Drug makers paid doctors millions to promote weight loss drugs like Ozempic to peers raising conflict concerns.

GLP-1 drugs can produce major weight loss, but their wider impact will depend on affordable treatment and appropriate support ...

Take a look at the Eli Lilly pipeline in 2026 as the incretin franchise grows and fuels the rest of the company's pipeline.

Ascletis Pharma has initiated a US Phase I study of oral amylin receptor agonist ASC36 in 86 participants with obesity or overweight, using its proprietary POTENT peptide delivery platform.

Eli Lilly and Company announced new phase 3b data, showing that combining ixekizumab (Taltz) with tirzepatide (Zepbound) produced improved and durable efficacy at 1 year in adults with psoriatic ...

Novo Nordisk's STEP Young trial shows 40.4% of children aged 6-11 achieved normal BMI with semaglutide. See Phase III results ...

On Aug. 12, Eli Lilly filed the first six lawsuits in its battle against the black market for its experimental weight-loss medication retatrutide.

The researchers noted that the Wisconsin Sleep Cohort Study found that a 10 percent gain in body weight was associated with a ...

Hong Kong-listed Gan & Lee Pharmaceuticals (1672.HK) has launched a Phase 1 clinical trial in the United States for ASC36, an oral amylin ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it has initiated a U.S. Phase I study of ASC36 oral ...

Novo Nordisk (NVO) said Monday its phase 3 Step Young trial evaluating once-weekly semaglutide in children aged six to under 12 with obesity met its primary endpoint. The treatmen ...

As a medical student in a larger body, I have often been ostracized, othered, made to feel different, like I’ve invaded a ...